{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:29:24Z","timestamp":1789435764968,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.07.065","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T09:45:26Z","timestamp":1501321526000},"page":"4851-4858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus"],"prefix":"10.1016","volume":"35","author":[{"given":"Sixun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doran","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hulse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Douglas","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0035-9203(55)90081-X","article-title":"An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952\u201353. II. General description and epidemiology","volume":"49","author":"Lumsden","year":"1955","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0035-9203(55)90080-8","article-title":"An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952\u201353. I. Clinical features","volume":"49","author":"Robinson","year":"1955","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.065_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0022172400044442","article-title":"The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic","volume":"54","author":"Ross","year":"1956","journal-title":"J Hyg (Lond)"},{"issue":"13","key":"10.1016\/j.vaccine.2017.07.065_b0020","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.01603-09","article-title":"Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates","volume":"84","author":"Volk","year":"2010","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.065_b0025","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/INF.0b013e3180616d4f","article-title":"Mother-to-child transmission of chikungunya virus infection","volume":"26","author":"Ramful","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"14\u201315","key":"10.1016\/j.vaccine.2017.07.065_b0030","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.micinf.2009.09.004","article-title":"Chikungunya: a bending reality","volume":"11","author":"Her","year":"2009","journal-title":"Microbes Infect"},{"issue":"14\u201315","key":"10.1016\/j.vaccine.2017.07.065_b0035","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.micinf.2009.09.003","article-title":"Immuno-biology of chikungunya and implications for disease intervention","volume":"11","author":"Kam","year":"2009","journal-title":"Microbes Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.065_b0040","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1097\/CCM.0b013e318183f2d2","article-title":"Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005\u20132006","volume":"36","author":"Lemant","year":"2008","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0045","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1017\/S0950268808001167","article-title":"Atypical chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005\u20132006 outbreak on Reunion","volume":"137","author":"Economopoulou","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2017.07.065_b0050","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1099\/vir.0.83628-0","article-title":"A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India","volume":"89","author":"Kumar","year":"2008","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0055","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4269\/ajtmh.2007.77.727","article-title":"A major epidemic of chikungunya virus infection on Reunion Island, France, 2005\u20132006","volume":"77","author":"Renault","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.065_b0060","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/517537","article-title":"Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients","volume":"44","author":"Borgherini","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1473-3099(07)70294-3","article-title":"Clinical burden of chikungunya virus infection","volume":"8","author":"Queyriaux","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.065_b0070","doi-asserted-by":"crossref","first-page":"e3066","DOI":"10.1371\/journal.pone.0003066","article-title":"Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005\u20132006: a population-based survey","volume":"3","author":"Sissoko","year":"2008","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.vaccine.2017.07.065_b0075","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya virus and the global spread of a mosquito-borne disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.065_b0080","first-page":"313","article-title":"Chikungunya virus infection. A retrospective study of 107 cases","volume":"63","author":"Brighton","year":"1983","journal-title":"S Afr Med J"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0085","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1371\/journal.pntd.0000389","article-title":"Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period","volume":"3","author":"Sissoko","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0090","doi-asserted-by":"crossref","first-page":"e0004281","DOI":"10.1371\/journal.pntd.0004281","article-title":"Long-lasting immune protection and other epidemiological findings after Chikungunya emergence in a cambodian rural community, April 2012","volume":"10","author":"Galatas","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.07.065_b0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1743-422X-11-183","article-title":"Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand","volume":"11","author":"Nitatpattana","year":"2014","journal-title":"Virol J"},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2017.07.065_b0100","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1099\/vir.0.2008\/005413-0","article-title":"Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa","volume":"89","author":"Kariuki Njenga","year":"2008","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.medmal.2011.12.002","article-title":"Epidemiology of Chikungunya infection on Reunion Island, Mayotte, and neighboring countries","volume":"42","author":"Renault","year":"2012","journal-title":"Med Mal Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.065_b0110","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1371\/journal.pmed.0030263","article-title":"Genome microevolution of Chikungunya viruses causing the Indian Ocean outbreak","volume":"3","author":"Schuffenecker","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.07.065_b0115","doi-asserted-by":"crossref","unstructured":"Paquet C et al. Chikungunya outbreak in Reunion: epidemiology and surveillance, 2005 to early January 2006. euro Surveill 2006;11(5). p. pii=2891.","DOI":"10.2807\/esw.11.05.02891-en"},{"issue":"9602","key":"10.1016\/j.vaccine.2017.07.065_b0120","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(07)61779-6","article-title":"Infection with chikungunya virus in Italy: an outbreak in a temperate region","volume":"370","author":"Rezza","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.065_b0125","article-title":"Chikungunya in north-eastern Italy: a summing up of the outbreak","volume":"12","author":"Angelini","year":"2007","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.07.065_b0130","doi-asserted-by":"crossref","unstructured":"Cassadou, S., et al., Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013. Euro Surveill 2014;19(13).","DOI":"10.2807\/1560-7917.ES2014.19.13.20752"},{"issue":"28","key":"10.1016\/j.vaccine.2017.07.065_b0135","doi-asserted-by":"crossref","first-page":"20855","DOI":"10.2807\/1560-7917.ES2014.19.28.20855","article-title":"Spread of chikungunya from the Caribbean to mainland Central and South America: a greater risk of spillover in Europe?","volume":"19","author":"Noel","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.07.065_b0140","doi-asserted-by":"crossref","unstructured":"Van Bortel W. et al. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill 2014;19(13).","DOI":"10.2807\/1560-7917.ES2014.19.13.20759"},{"issue":"22","key":"10.1016\/j.vaccine.2017.07.065_b0145","first-page":"500","article-title":"Notes from the field: chikungunya virus spreads in the Americas \u2013 Caribbean and South America, 2013\u20132014","volume":"63","author":"Fischer","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"48","key":"10.1016\/j.vaccine.2017.07.065_b0150","first-page":"1121","article-title":"Chikungunya cases identified through passive surveillance and household investigations\u2013Puerto Rico, May 5-August 12, 2014","volume":"63","author":"Sharp","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"48","key":"10.1016\/j.vaccine.2017.07.065_b0155","first-page":"1137","article-title":"Notes from the field: transmission of chikungunya virus in the continental United States-Florida, 2014","volume":"63","author":"Kendrick","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.vaccine.2017.07.065_b0160","doi-asserted-by":"crossref","first-page":"11644","DOI":"10.1128\/JVI.01432-14","article-title":"Reemergence of chikungunya virus","volume":"88","author":"Morrison","year":"2014","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virusres.2008.02.004","article-title":"Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates","volume":"135","author":"Santhosh","year":"2008","journal-title":"Virus Res"},{"issue":"12","key":"10.1016\/j.vaccine.2017.07.065_b0170","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1371\/journal.ppat.0030201","article-title":"A single mutation in chikungunya virus affects vector specificity and epidemic potential","volume":"3","author":"Tsetsarkin","year":"2007","journal-title":"PLoS Pathog"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.065_b0175","doi-asserted-by":"crossref","first-page":"e1168","DOI":"10.1371\/journal.pone.0001168","article-title":"Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus","volume":"2","author":"Vazeille","year":"2007","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0180","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1179\/2047773215Y.0000000017","article-title":"Do we need a vaccine against chikungunya?","volume":"109","author":"Rezza","year":"2015","journal-title":"Pathog Glob Health"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.065_b0185","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/fvl-2016-0067","article-title":"Vaccines against chikungunya, Zika and other emerging Aedes mosquito-borne viruses: unblocking existing bottlenecks","volume":"11","author":"Rezza","year":"2016","journal-title":"Future Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0190","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/vbz.2014.1681","article-title":"Therapeutics and vaccines against chikungunya virus","volume":"15","author":"Ahola","year":"2015","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.065_b0195","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/erv.12.84","article-title":"Chikungunya virus and prospects for a vaccine","volume":"11","author":"Weaver","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"9959","key":"10.1016\/j.vaccine.2017.07.065_b0200","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.065_b0205","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","author":"Edelman","year":"2000","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0210","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.107.3.643","article-title":"Production and evaluation of a formalin-killed Chikungunya vaccine","volume":"107","author":"Harrison","year":"1971","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0264-410X(86)90003-4","article-title":"Development of an attenuated strain of chikungunya virus for use in vaccine production","volume":"4","author":"Levitt","year":"1986","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.065_b0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2017.07.065_b0225","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1016\/j.vaccine.2012.08.025","article-title":"US Military contributions to the global response to pandemic chikungunya","volume":"30","author":"Hoke","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0230","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/514240","article-title":"Immunologic interference from sequential administration of live attenuated alphavirus vaccines","volume":"177","author":"McClain","year":"1998","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.065_b0235","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1086\/605496","article-title":"Chikungunya fever: an epidemiological review of a re-emerging infectious disease","volume":"49","author":"Staples","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2017.07.065_b0240","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/S0264-410X(00)00006-2","article-title":"Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area","volume":"18","author":"Richie","year":"2000","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.065_b0245","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.trstmh.2010.01.011","article-title":"Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging","volume":"104","author":"Manimunda","year":"2010","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.065_b0250","doi-asserted-by":"crossref","first-page":"e0003764","DOI":"10.1371\/journal.pntd.0003764","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.065_b0255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-3024.2000.00326.x","article-title":"Potentiation of vesicular stomatitis New Jersey virus infection in mice by mosquito saliva","volume":"22","author":"Limesand","year":"2000","journal-title":"Parasite Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/vim.2006.19.74","article-title":"Potentiation of West Nile encephalitis by mosquito feeding","volume":"19","author":"Schneider","year":"2006","journal-title":"Viral Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.065_b0265","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-3024.2009.01096.x","article-title":"SAAG-4 is a novel mosquito salivary protein that programmes host CD4T cells to express IL-4","volume":"31","author":"Boppana","year":"2009","journal-title":"Parasite Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.065_b0270","doi-asserted-by":"crossref","first-page":"e12137","DOI":"10.1371\/journal.pone.0012137","article-title":"Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by needle inoculated virus","volume":"5","author":"Thangamani","year":"2010","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.vaccine.2017.07.065_b0275","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1128\/JVI.00291-08","article-title":"Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo","volume":"82","author":"Goncalvez","year":"2008","journal-title":"J Virol"},{"issue":"45","key":"10.1016\/j.vaccine.2017.07.065_b0280","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0285","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0290","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/600381","article-title":"Prophylaxis and therapy for Chikungunya virus infection","volume":"200","author":"Couderc","year":"2009","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0295","doi-asserted-by":"crossref","first-page":"e1003312","DOI":"10.1371\/journal.ppat.1003312","article-title":"Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus","volume":"9","author":"Pal","year":"2013","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0300","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.065_b0305","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/JVI.03418-13","article-title":"A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection","volume":"88","author":"Garcia-Arriaza","year":"2014","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.065_b0310","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JVI.03453-13","article-title":"Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice","volume":"88","author":"Hallengard","year":"2014","journal-title":"J Virol"},{"issue":"22","key":"10.1016\/j.vaccine.2017.07.065_b0315","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1128\/JVI.01926-14","article-title":"Prime-boost immunization strategies against Chikungunya virus","volume":"88","author":"Hallengard","year":"2014","journal-title":"J Virol"},{"issue":"43","key":"10.1016\/j.vaccine.2017.07.065_b0320","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1016\/j.vaccine.2012.07.072","article-title":"Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus","volume":"30","author":"Kumar","year":"2012","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2017.07.065_b0325","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of Chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J Immunol"},{"issue":"33","key":"10.1016\/j.vaccine.2017.07.065_b0330","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.vaccine.2013.05.059","article-title":"Deciphering the protective role of adaptive immunity to CHIKV\/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model","volume":"31","author":"Chu","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0335","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.065_b0340","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.1202177","article-title":"A pathogenic role for CD4+T cells during Chikungunya virus infection in mice","volume":"190","author":"Teo","year":"2013","journal-title":"J Immunol"},{"issue":"36","key":"10.1016\/j.vaccine.2017.07.065_b0350","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.065_b0355","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.ppat.0040029","article-title":"A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease","volume":"4","author":"Couderc","year":"2008","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.vaccine.2017.07.065_b0360","doi-asserted-by":"crossref","first-page":"e3354","DOI":"10.1371\/journal.pntd.0003354","article-title":"Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection","volume":"8","author":"Poo","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.065_b0365","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.4049\/jimmunol.1103185","article-title":"Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to Chikungunya infection","volume":"188","author":"Schilte","year":"2012","journal-title":"J Immunol"},{"issue":"16","key":"10.1016\/j.vaccine.2017.07.065_b0370","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1128\/JVI.02603-09","article-title":"Chikungunya virus arthritis in adult wild-type mice","volume":"84","author":"Gardner","year":"2010","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0375","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1172\/JCI40104","article-title":"Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages","volume":"120","author":"Labadie","year":"2010","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0380","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1086\/590003","article-title":"Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on Reunion Island","volume":"47","author":"Borgherini","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.065_b0385","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.4049\/jimmunol.0900255","article-title":"Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response","volume":"184","author":"Hoarau","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.07.065_b0390","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2334-9-200","article-title":"Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies","volume":"9","author":"Malvy","year":"2009","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.065_b0395","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1471-4906(03)00065-6","article-title":"Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection","volume":"24","author":"Suhrbier","year":"2003","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.065_b0400","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.antiviral.2013.03.018","article-title":"Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection","volume":"98","author":"Sasaki","year":"2013","journal-title":"Antiviral Res"},{"issue":"13","key":"10.1016\/j.vaccine.2017.07.065_b0405","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"issue":"5807","key":"10.1016\/j.vaccine.2017.07.065_b0410","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/290590a0","article-title":"Acute rabies death mediated by antibody","volume":"290","author":"Prabhakar","year":"1981","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.065_b0415","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2017.07.065_b0420","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","article-title":"Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"39","author":"Castilow","year":"2007","journal-title":"Immunol Res"},{"issue":"13","key":"10.1016\/j.vaccine.2017.07.065_b0425","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1128\/JVI.77.13.7539-7544.2003","article-title":"Antibody-dependent enhancement of Ebola virus infection","volume":"77","author":"Takada","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.065_b0430","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","article-title":"Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple","volume":"62","author":"Polack","year":"2007","journal-title":"Pediatr Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:14:37Z","timestamp":1692904477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17309738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":86,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17309738"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}